摘要
Ⅰ期非小细胞肺癌（NSCLC）临床预后因素包括肿瘤大小和患者年龄、手术方式和胸膜浸润情况等。分子生物学预后因素包括肿瘤细胞信号通路中的表皮生长因子及其受体、细胞周期素和凋亡基因Bcl-2、p53的异常表达等，以及肿瘤血管生成中基质金属蛋白酶（MMP）、血管内皮生长因子（VEGF）的异常表达等。因此，需要将Ⅰ期NSCLC临床和分子生物学预后因素两方面综合考虑，才能准确判断预后。
The clinical prognostic factors in stage Ⅰ non-small cell lung cancer include tumor size, patients age, surgery modes and pleura involving. Abnormal molecular mechanisms including epidemical growth factors and its receptors, cyclin and apoptosis related genes such as Bcl-2 and p53, matrix metalloproteinases and vascular growth factors in tumor angiogenesis and lymphangiogenesis are involved in survival, of stage Ⅰ nonsmall cell lung cancer patients. So, we need integrate the clinical and molecular prognostic factors so that we could estimate the prognosis of stage Ⅰ non-small cell lung cancer accurately.
出处
《国际肿瘤学杂志》
CAS
2008年第2期127-130,共4页
Journal of International Oncology
基金
广东省科技攻关重大项目（20078031515017）
关键词
癌
非小细胞肺
信号传导
血管内皮生长因子类
基质金属蛋白酶类
预后
Carcinoma, non- small- cell lung
Signal transduction
Vascular endothelial growth fac tors
Matrix metalloproteinases
Prognosis
